Weight-Loss Medication Comparison Chart Philadelphia
Compare FDA-approved and traditional weight-loss medications in
Philadelphia, including expected results, route, safety, insurance coverage
and affordable W8MD treatment options.
prescription weight-loss pills and comprehensive medical weight-management
plans. Original W8MD image; © W8MD Weight Loss, Sleep & MedSpa. Used
with permission.
Weight-loss medication comparison
Prescription weight-loss medications work through different mechanisms.
Some primarily reduce appetite, while others increase fullness, influence
food-reward pathways or decrease absorption of dietary fat. The best option
depends on medical history, expected benefits, contraindications, side
effects, insurance coverage, treatment goals and long-term affordability.
| Option | Route | General role | Selected considerations |
|---|---|---|---|
| Wegovy / semaglutide | Weekly injection or approved daily tablet | Chronic weight management |
Gastrointestinal effects, thyroid warning, gallbladder and pancreatic history, dehydration risk, pregnancy and insurance coverage |
| Zepbound / tirzepatide | Weekly injection |
Chronic weight management; also has an obstructive sleep-apnea indication for defined adults with obesity |
Gastrointestinal effects, thyroid warning, pregnancy, gallbladder and pancreatic history, dehydration and product-specific oral contraceptive instructions |
| Foundayo / orforglipron | Daily tablet | FDA-approved oral GLP-1 treatment for chronic weight management |
A newer oral option; coverage, formulary placement, availability, contraindications and product-specific interactions must be reviewed |
| Qsymia | Daily extended-release capsule | Chronic weight management using phentermine and topiramate |
Pregnancy prevention, stimulant effects, heart rate, mood, cognition, glaucoma, kidney stones and metabolic acidosis |
| Contrave | Oral medication with gradual dose escalation | Chronic weight management using naltrexone and bupropion |
Seizure risk, blood pressure, opioid use, eating disorders, interactions and mental-health warnings |
| Orlistat | Oral medication taken with fat-containing meals | Reduces absorption of some dietary fat and does not act as a stimulant |
Gastrointestinal effects, fat-soluble vitamins, kidney risks, diet composition and medication interactions |
| Phentermine | Oral medication | Traditional appetite suppressant with a short-term FDA indication |
Blood pressure, heart rate, cardiovascular history, anxiety, sleep, interactions and controlled-substance requirements |
| Diethylpropion or phendimetrazine | Oral medication | Alternative short-term appetite suppressants for selected patients |
Cardiovascular risk, blood pressure, sleep, anxiety, interactions, tolerance and controlled-substance requirements |
Clinical trials may differ in population, duration, diabetes status,
adherence, dose and statistical methods. A trial average cannot predict an
individual patient’s result.
GLP-1 injections compared with phentermine
GLP-1 and related treatment
Semaglutide and tirzepatide influence appetite and fullness pathways.
They generally produced greater average weight reduction than older oral
medications in major trials, but they can be costly and commonly cause
gastrointestinal effects.
They may receive additional consideration when diabetes, cardiovascular
risk or obesity-related obstructive sleep apnea is relevant, subject to
the indication of the selected product.
Phentermine
Phentermine is a traditional oral appetite suppressant. It may be
substantially less expensive and may suit an eligible patient who prefers
a tablet and does not have relevant contraindications.
It requires appropriate cardiovascular, blood-pressure, anxiety, sleep
and interaction screening. It is not appropriate for every patient.
Phentermine/topiramate
Combining phentermine with topiramate can provide greater weight reduction
than phentermine alone. Qsymia is the FDA-approved extended-release
combination.
Pregnancy prevention is especially important because topiramate exposure
can harm a developing fetus. Mood, cognition, glaucoma, kidney stones and
metabolic effects must also be considered.
Beyond “which drug loses the most?”
The best treatment must be medically acceptable, affordable, available and
compatible with the patient’s life. The newest medication or the medication
associated with the largest average clinical-trial result is not
automatically the best choice for every patient.
Route, cultural eating pattern, fasting or meal schedule, gastrointestinal
tolerance, constipation risk, work demands, pregnancy plans, sleep apnea,
cardiovascular disease, diabetes, kidney or liver health, prior treatment
response and insurance coverage can all change the ranking.
Semaglutide-based options start from
$29.99 per week when insurance is accepted for qualifying
medical visits. Self-pay semaglutide options start from
$59.99 per week.
Tirzepatide-based options start from
$45 per week when insurance is accepted for qualifying
medical visits. Self-pay tirzepatide options start from
$69.99 per week.
Dose, eligibility, pharmacy, availability, insurance, copay, deductible,
visit costs and program components affect the final cost. Medical-visit
coverage is separate from pharmacy coverage. Confirm current details on the
Philadelphia cost page
.
How W8MD can help
W8MD physicians bring more than 20 years of experience in obesity and
metabolic care. The goal is not to prescribe the newest or most expensive
option automatically. W8MD helps each patient identify a reasonable plan
based on medical conditions, previous attempts, appetite patterns, sleep,
current medications, mobility, preferences, cultural food traditions,
insurance coverage and budget.
Medical assessment
W8MD reviews BMI and weight-related complications, blood pressure,
cardiovascular and sleep risks, diabetes status, kidney and liver health,
reproductive plans, mental health, contraindications and medication
interactions.
Individualized nutrition
Plans can accommodate South Asian, East Asian, Caribbean, African, Latino,
Mediterranean, vegetarian, kosher, halal and other household food
patterns without treating culture as a barrier.
Cost and coverage
W8MD compares traditional generic medications, FDA-approved brand-name
treatments, insurance criteria, prior authorization, self-pay pricing and
the total cost of monitoring.
Long-term support
Follow-up addresses treatment response, side effects, protein and
hydration, sleep, muscle preservation, plateaus and prevention of weight
regain.
Frequently asked questions
Who qualifies for chronic weight-loss medication?
Many product labels use a BMI of 30 or greater, or a BMI of 27 or greater
with a weight-related medical condition. Each product has its own
indications and contraindications. Meeting a BMI threshold does not
guarantee that a particular medication is appropriate.
Is a generic weight-loss medication inferior?
Not automatically. Some generic medications are effective and affordable
for carefully selected patients. Newer medicines may produce greater
average weight reduction but have different side effects, contraindications
and costs.
Does insurance cover obesity medication?
Coverage varies by employer and health plan. Medical-visit coverage and
pharmacy coverage are separate benefits. Some plans exclude obesity
medications, while others require prior authorization or step therapy.
Can W8MD guarantee insurance approval?
No. W8MD may document clinical eligibility and assist with prior
authorization when coverage exists, but the insurer or pharmacy-benefit
manager makes the approval decision.
Which works better: GLP-1 treatment or phentermine?
Semaglutide and tirzepatide generally produced greater average weight
reduction in major clinical trials. However, they were not tested against
every alternative in identical populations. Phentermine may remain a useful
and affordable option for selected patients.
Can phentermine be combined with a GLP-1 medication?
Some combinations may be considered off-label in selected patients, but
safety and effectiveness data may be limited. Combination treatment
requires individualized physician evaluation and monitoring.
Related Philadelphia resources
Continue on this site
W8MD network
WikiMD encyclopedia
Evidence and authoritative information
-
American Gastroenterological Association guideline on pharmacological
interventions for adults with obesity
-
ADA Standards of Care 2026: obesity and weight management
W8MD Northeast Philadelphia
1718 Welsh Road, 2nd Floor, Suite C
Philadelphia, PA 19115
Phone:
215-676-2334
Serving Northeast Philadelphia and patients from Bucks County, Montgomery
County, Delaware County, Center City, the Pennsylvania suburbs and nearby
South Jersey, subject to clinical and licensure requirements.
Contact W8MD Philadelphia
Use the form for nonurgent appointment and service questions. Do not submit
emergency symptoms or highly sensitive information.
This page provides general education and is not a diagnosis, individualized
medical advice or a prescription. Treatment requires a clinical evaluation
of indications, contraindications, interactions and alternatives. Never
start, stop, combine, share or change prescription medication without
guidance from the prescriber. Medical weight-loss results vary. Call 911 for
an emergency. Reviewed August 23, 2026.
